Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dermal corrosivity tests

This article was originally published in The Tan Sheet

Executive Summary

Interagency Coordinating Committee on Validation of Alternative Methods releases final recommendations accepting three animal alternative methods to test dermal corrosivity, National Institute of Environmental Health Sciences announces in 1July 31 Federal Register notice. Expedited review of EpiDerm, EPISKIN and Rat Skin Transcutaneous Electrical Resistance tests was initiated following endorsement by European Centre for the Validation of Alternative Methods Scientific Advisory Committee. ICCVAM recommends the three tests can be used to measure dermal corrosivity in a "weight-of-evidence approach using an integrated testing scheme"...

You may also be interested in...



ICCVAM/ECVAM Early Collaboration Explored To Hasten Animal Alternatives

Faster validation of animal alternative test methods is dependent upon increased collaboration between the Interagency Coordinating Committee for the Validation of Alternative Methods and the European Centre for the Validation of Alternative Methods, according to leaders of both groups

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel